Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

ENTO

Entero Therapeutics Inc.

Oct 08 • 04:00PM ET

0.4190

Dollar change -0.1009
Percentage change -19.41	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-49.23	Insider Own	2.92%	Shs Outstand	3.25M	Perf Week	30.94%
Market Cap	1.36M	Forward P/E	-	EPS next Y	-	Insider Trans	-1.97%	Shs Float	3.16M	Perf Month	4.75%
Income	-6.44M	PEG	-	EPS next Q	-	Inst Own	4.55%	Short Float	4.03%	Perf Quarter	-62.25%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.17	Perf Half Y	-88.52%
Book/sh	7.99	P/B	0.05	EPS next Y	-	ROA	-12.74%	Short Interest	0.13M	Perf Year	-93.65%
Cash/sh	1.06	P/C	0.40	EPS next 5Y	-	ROE	-15.28%	52W Range	0.19 - 14.51	Perf YTD	-90.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	73.53%	ROI	-7.64%	52W High	-97.11%	Beta	1.26
Dividend TTM	-	Quick Ratio	1.21	Sales past 5Y	0.00%	Gross Margin	-	52W Low	126.49%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	1.21	EPS Y/Y TTM	94.30%	Oper. Margin	0.00%	RSI (14)	50.89	Volatility	42.19% 21.18%
Employees	9	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	36.00
Option/Short	No / Yes	LT Debt/Eq	0.08	EPS Q/Q	101.05%	Payout	-	Rel Volume	1.50	Prev Close	0.52
Sales Surprise	-	EPS Surprise	149.35%	Sales Q/Q	-	Earnings	May 20	Avg Volume	744.60K	Price	0.42
SMA20	13.72%	SMA50	3.60%	SMA200	-84.97%	Trades		Volume	1,118,666	Change	-19.41%

Sep-10-24 07:00AM	Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings (GlobeNewswire)
Aug-23-24 05:00PM	Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q (GlobeNewswire) +5.78%
Jul-31-24 07:00AM	Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program (GlobeNewswire) +6.04%
Jul-11-24 08:00AM	Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds (GlobeNewswire)
Jul-09-24 07:00AM	Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium (GlobeNewswire) +17.31%
07:34AM	Loading…
Jun-27-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -30.23%
06:00AM	Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease (GlobeNewswire)
May-22-24 07:00AM	Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention (GlobeNewswire)
May-20-24 07:00AM	Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference (GlobeNewswire)
May-16-24 07:00AM	First Wave BioPharma Changes Name to Entero Therapeutics (GlobeNewswire)
May-15-24 09:52AM	FWBI Stock Earnings: First Wave BioPharma Beats EPS for Q1 2024 (InvestorPlace)
May-10-24 07:55AM	First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market (GlobeNewswire)
May-09-24 07:00AM	First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-24-24 07:00AM	First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients (GlobeNewswire)
07:00AM	Loading…
Apr-17-24 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase (GlobeNewswire)
Apr-15-24 07:00AM	First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference (GlobeNewswire)
Apr-05-24 09:55AM	Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-27-24 12:00PM	First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-18-24 07:00AM	First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference (GlobeNewswire)
Mar-14-24 08:05AM	Why Is First Wave BioPharma (FWBI) Stock Up Today? (InvestorPlace) -17.76%
06:00AM	First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline (GlobeNewswire)
Mar-05-24 07:00AM	First Wave BioPharma to Participate In 'Fireside Chat' at the 36th Annual Roth Conference (GlobeNewswire) +11.10%
Mar-04-24 08:00AM	First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering (GlobeNewswire) -23.92%
Feb-13-24 07:00AM	First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024 (GlobeNewswire) -9.11%
Jan-23-24 07:00AM	First Wave BioPharma to Present at the DealFlow MicroCap Conference (GlobeNewswire)
Jan-17-24 07:00AM	First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico (GlobeNewswire)
Jan-04-24 06:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024 (GlobeNewswire)
Dec-27-23 11:55AM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced (GlobeNewswire) +49.86%
10:29AM	Why Is First Wave Biopharma (FWBI) Stock Up 148% Today? (InvestorPlace)
06:00AM	Loading…
06:00AM	First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program (GlobeNewswire)
Dec-20-23 10:03AM	FWBI Stock Earnings: First Wave BioPharma Reported Results for Q1 2023 (InvestorPlace)
10:03AM	FWBI Stock Earnings: First Wave BioPharma Beats EPS for Q3 2023 (InvestorPlace)
Dec-18-23 06:00AM	First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company (GlobeNewswire) -22.14%
Dec-14-23 09:15AM	First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders (GlobeNewswire) -16.78%
Dec-06-23 07:00AM	First Wave BioPharma to Participate in BIO Partnering @JPM During J.P. Morgan Week 2024 (GlobeNewswire)
Dec-05-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference (GlobeNewswire)
Oct-10-23 07:00AM	Date and Time Announced for First Wave BioPharma CEO James Sapirstein's Presentation at the 2023 BIO Investor Forum (GlobeNewswire)
Oct-03-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference (GlobeNewswire)
Sep-15-23 08:45AM	First Wave BioPharma To Present at the BIO Investor Forum (GlobeNewswire) -13.39%
Sep-14-23 10:43AM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) +16.75%
06:00AM	First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi (GlobeNewswire)
Sep-05-23 07:00AM	First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +55.17%
Jul-19-23 08:15AM	First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering (GlobeNewswire)
Jul-13-23 07:00AM	First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation (GlobeNewswire) -32.46%
Jul-05-23 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire)
Jun-28-23 07:00AM	First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire)
Jun-27-23 07:00AM	First Wave BioPharma Strengthens Intellectual Property Estate (GlobeNewswire) -6.51%
Jun-15-23 11:31AM	First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30) (GlobeNewswire) +8.57%
Jun-13-23 12:50PM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) +33.12%
07:00AM	First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
May-15-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference (GlobeNewswire)
May-11-23 07:00AM	First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
May-02-23 07:30AM	First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference (GlobeNewswire) -7.14%
Apr-25-23 07:00AM	First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
Mar-13-23 08:00AM	First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (GlobeNewswire) -16.76%
07:00AM	HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors (GlobeNewswire)
Mar-10-23 07:00AM	First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis (GlobeNewswire)
Mar-09-23 07:00AM	First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire) +6.48%
Feb-28-23 07:00AM	First Wave BioPharma to Participate in Fireside Chat at the 35th Annual Roth Conference (GlobeNewswire)
Feb-21-23 07:00AM	First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference (GlobeNewswire) +7.14%
Feb-13-23 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire) -6.30%
Feb-07-23 07:00AM	First Wave BioPharma Regains Compliance With Nasdaqs Minimum Bid Price Requirement (GlobeNewswire)
Feb-02-23 07:00AM	First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis (GlobeNewswire) +5.03%
Jan-31-23 07:00AM	First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis (GlobeNewswire) -7.51%
Jan-30-23 07:00AM	First Wave BioPharma to Present at the BIO CEO & Investor Conference (GlobeNewswire) +7.92%
Jan-25-23 07:00AM	First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio (GlobeNewswire) +22.17%
Jan-24-23 07:00AM	First Wave BioPharma to Present at Sequire Biotechnology Conference (GlobeNewswire)
Jan-13-23 04:00PM	First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency (GlobeNewswire) -11.99%
10:20AM	First Wave BioPharma Announces Results of Special Meeting of Stockholders (GlobeNewswire)
Jan-09-23 09:10AM	First Wave BioPharma Announces Adjournment of Special Meeting (GlobeNewswire) -13.33%
Jan-05-23 09:45AM	ZyVersa Therapeutics Appoints Three New Board Members (PR Newswire)
Dec-12-22 07:30AM	First Wave BioPharma to Participate in BIO Partnering @ JPM During J.P. Morgan Week 2023 (GlobeNewswire)
Dec-05-22 07:00AM	First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase (GlobeNewswire)
Nov-30-22 07:00AM	First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase (GlobeNewswire) +5.60%
Nov-25-22 05:45PM	First Wave BioPharma Announces Distribution of Series F Preferred Stock to Holders of Its Common Stock (GlobeNewswire) +16.91%
Nov-22-22 04:15PM	First Wave BioPharma, Inc. Announces Closing of Private Placement (GlobeNewswire)
Nov-21-22 08:00AM	First Wave BioPharma, Inc. Announces Private Placement (GlobeNewswire) -11.61%
Nov-16-22 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire)
Oct-31-22 07:00AM	First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire)
Oct-11-22 05:30PM	First Wave BioPharma, Inc. Announces Closing of $6.0 Million Public Offering (GlobeNewswire)
Oct-10-22 07:00AM	First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360 (GlobeNewswire)
Oct-06-22 09:00PM	First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering (GlobeNewswire) -11.96% -6.17%
08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews James Sapirstein CEO, First Wave BioPharma, Inc. (ACCESSWIRE)
Sep-28-22 07:00AM	First Wave BioPharmas CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference (GlobeNewswire)
Sep-19-22 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire) -9.25%
Sep-14-22 07:00AM	First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference (GlobeNewswire) -12.15%
Sep-07-22 07:00AM	First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation (GlobeNewswire) -23.22%
Aug-31-22 07:00AM	First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract (GlobeNewswire) -5.54%
Aug-29-22 07:00AM	First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022 (GlobeNewswire)
Aug-25-22 12:00PM	First Wave BioPharma, Inc. Announces Reverse Stock Split (GlobeNewswire) -18.18%
Jul-15-22 08:00AM	First Wave BioPharma, Inc. Announces Private Placement (GlobeNewswire) -21.38%
May-17-22 07:00AM	First Wave BioPharma to Participate in Fireside Chat at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.94%
Apr-29-22 04:30PM	First Wave BioPharma Chairman and CEO Issues Letter to Shareholders (GlobeNewswire) -35.42%
Apr-27-22 07:00AM	First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio (GlobeNewswire)
Mar-31-22 08:15AM	Goldman Small Cap Research Publishes New Research Report on First Wave BioPharma, Inc. (ACCESSWIRE)
Mar-28-22 04:23PM	First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19 (GlobeNewswire)
Mar-22-22 07:00AM	First Wave BioPharma to Participate in Maxims 2022 Virtual Growth Conference (GlobeNewswire)
Mar-08-22 07:00AM	First Wave BioPharma to Participate in Fireside Chat at the 34th Annual Roth Conference (GlobeNewswire)
Mar-03-22 07:00AM	First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference (GlobeNewswire)

Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Romano Sarah	Chief Financial Officer	Jul 02 '24	Sale	1.07	621	664	18,490	Jul 03 02:34 PM
SAPIRSTEIN JAMES	Chairman and CEO	Jul 02 '24	Sale	1.07	1,289	1,379	35,816	Jul 03 02:33 PM
SAPIRSTEIN JAMES	Chairman and CEO	Apr 01 '24	Sale	4.23	174	736	37,105	Apr 03 05:14 PM
Romano Sarah	Chief Financial Officer	Apr 01 '24	Sale	4.23	75	317	19,111	Apr 03 05:13 PM
SAPIRSTEIN JAMES	Chairman and CEO	Mar 15 '24	Sale	4.96	1,887	9,360	37,279	Mar 19 04:13 PM
Romano Sarah	Chief Financial Officer	Mar 15 '24	Sale	4.96	1,120	5,555	19,186	Mar 19 04:10 PM
Romano Sarah	Chief Financial Officer	Jan 12 '24	Sale	4.20	98	412	20,306	Jan 17 04:02 PM
SAPIRSTEIN JAMES	Chairman, President and CEO	Jan 12 '24	Sale	4.20	166	697	39,166	Jan 17 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTO

Entero Therapeutics Inc.

Upgrade your FINVIZ experience